Procyon Revenue Growth Rates (PCYN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Procyon Corporation  (PCYN)
 

PCYN's Revenue Growth by Quarter and Year

Procyon's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PCYN Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter June 1.41
3rd Quarter March 1.20
2nd Quarter December 1.20
1st Quarter September 1.17
FY 4.98

PCYNs Annual Revenue
Procyon's Revenue in the fiscal year 2024 $ 4.98 millions
Procyon's Revenue in the fiscal year 2023 $ 4.69 millions
Procyon's Revenue in the fiscal year 2022 $ 4.84 millions
Procyon's Revenue in the fiscal year 2021 $ 4.72 millions
Procyon's Revenue in the fiscal year 2020 $ 4.33 millions




PCYN Revenue fourth quarter 2024 Y/Y Growth Comment
Procyon Corporation achieved in the fourth quarter 2024, above Company average Revenue increase of 17.73% year on year, to $ 1.41 millions.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue growth. While Procyon Corporation' s Revenue growth of 17.73% ranks overall at the positon no. 769 in the fourth quarter 2024.


PCYN Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter June 17.73 % -0.83 % -4.72 % 44.32 %
3rd Quarter March 7.14 % 0.9 % 7.77 % -9.65 %
2nd Quarter December 1.69 % -11.28 % 13.68 % 3.54 %
1st Quarter September -0.85 % -0.84 % -4.8 % 5.93 %
FY   6.47 % -3.31 % 2.54 % -

Financial Statements
Procyon's fourth quarter 2024 Revenue $ 1.41 millions PCYN's Income Statement
Procyon's fourth quarter 2023 Revenue $ 1.20 millions Quarterly PCYN's Income Statement


PCYN Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter June 17.73 % 7.14 % 9.01 % 23.3 %
3rd Quarter March 0 % -5.08 % -16.54 % -11.97 %
2nd Quarter December 2.56 % 0 % 11.76 % -6.4 %
1st Quarter September -2.5 % -2.48 % -6.3 % 42.05 %
FY (Year on Year)   6.47 % -3.31 % 2.54 % -


Back to PCYN Growth rate Comparisons >> Back to PCYN Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #202
Overall #769

Revenue Y/Y Growth Statistics
High Average Low
43.16 % 6.1 % -20.74 %
(Jun 30 2021)   (Jun 30 2020)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #202
Overall #769
Revenue Y/Y Growth Statistics
High Average Low
43.16 % 6.1 % -20.74 %
(Jun 30 2021)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Procyon's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
40.98 % 0.55 % -100 %
(Sep 30 2020)  


PCYN's IV. Quarter Q/Q Revenue Comment
Procyon Corporation achieved in the IV. Quarter 2024 above company average sequential Revenue jump of 17.73%, to $ 1.41 millions, from $1.20 millions in the third quarter.
PCYN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 88 other companies have achieved higher Revenue quarter on quarter growth. While Procyon's Revenue growth quarter on quarter, overall rank is 680.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #177
Overall #680
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #89
Healthcare Sector #177
Overall #680
Revenue Q/Q Growth Statistics
High Average Low
40.98 % 0.55 % -100 %
(Sep 30 2020)  


PCYN's IV. Quarter Q/Q Revenue Comment
Procyon Corporation achieved in the IV. Quarter 2024 above company average sequential Revenue jump of 17.73%, to $ 1.41 millions, from $1.20 millions in the third quarter.
PCYN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 88 other companies have achieved higher Revenue quarter on quarter growth. While Procyon's Revenue growth quarter on quarter, overall rank is 680.


Procyon's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 4.98 $ 4.77 $ 4.70 $ 4.68 $ 4.69
Y / Y Revenue Growth (TTM) 6.35 % 1.71 % 0.4 % -2.98 % -3.22 %
Year on Year Revenue Growth Overall Ranking # 2309 # 1790 # 993 # 1690 # 2277
Seqeuential Revenue Change (TTM) 4.41 % 1.57 % 0.34 % -0.06 % -0.15 %
Seq. Revenue Growth (TTM) Overall Ranking # 1995 # 1482 # 995 # 1980 # 2571


Cumulative Revenue growth Comment
Procyon saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 6.35% year on year, to $ 5 millions if the fiscal year would have ended in Jun 30 2024.
Procyon's trailing twelve months Revenue growth was higher than company's average 5.39% and higher than 1.71% growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 4.41 % from $4.77 millions achieved in the period from Mar 31 2024 to Jun 30 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5.39%.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 4.41 % increase from $4.77 millions in the period from Mar 31 2024 to Jun 30 2023.

In the Healthcare sector 371 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1790 to 2309.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 125
Healthcare Sector # 372
Overall # 2309

Revenue TTM Y/Y Growth Statistics
High Average Low
25.33 %
 5.39 %
-10.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 125
Sector # 343
S&P 500 # 1995
Cumulative Revenue growth Comment
Procyon saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 6.35% year on year, to $ 5 millions if the fiscal year would have ended in Jun 30 2024.
Procyon's trailing twelve months Revenue growth was higher than company's average 5.39% and higher than 1.71% growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 4.41 % from $4.77 millions achieved in the period from Mar 31 2024 to Jun 30 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5.39%.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 4.41 % increase from $4.77 millions in the period from Mar 31 2024 to Jun 30 2023.

In the Healthcare sector 371 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1790 to 2309.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 125
Healthcare Sector # 372
Overall # 2309

Revenue TTM Y/Y Growth Statistics
High Average Low
25.33 %
5.39 %
-10.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 125
Sector # 343
S&P 500 # 1995




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PCYN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Recursion Pharmaceuticals Inc 30.86%$ 30.861 millions
Lyra Therapeutics Inc 30.57%$ 30.568 millions
Neurocrine Biosciences Inc 30.37%$ 30.373 millions
Scilex Holding Company30.11%$ 30.107 millions
Poseida Therapeutics Inc 29.78%$ 29.781 millions
Sanara Medtech Inc 29.45%$ 29.453 millions
Avita Medical Inc 29.29%$ 29.286 millions
Guardant Health Inc 29.23%$ 29.227 millions
Inspire Medical Systems inc 29.09%$ 29.088 millions
Agilon Health Inc 29.04%$ 29.042 millions
Talkspace Inc 28.91%$ 28.913 millions
Harmony Biosciences Holdings inc 28.65%$ 28.651 millions
Agios Pharmaceuticals Inc 28.35%$ 28.352 millions
Lipella Pharmaceuticals Inc 27.89%$ 27.893 millions
Genmab A27.84%$ 27.842 millions
Twist Bioscience Corporation27.81%$ 27.807 millions
The Pennant Group Inc 27.57%$ 27.566 millions
Viemed Healthcare Inc 26.91%$ 26.908 millions
International Stem Cell Corporation26.62%$ 26.616 millions
Xeris Biopharma Holdings Inc 26.46%$ 26.460 millions
Immunocore Holdings Plc26.18%$ 26.178 millions
Dih Holding Us Inc 26.14%$ 26.140 millions
Precipio inc 25.70%$ 25.701 millions
Axogen inc 25.57%$ 25.572 millions
Amphastar Pharmaceuticals Inc 25.17%$ 25.174 millions
Vireo Growth Inc.24.32%$ 24.319 millions
Supernus Pharmaceuticals inc 24.17%$ 24.167 millions
Alphatec Holdings Inc 24.07%$ 24.071 millions
Novo Nordisk A23.74%$ 23.743 millions
Catalent Inc 23.32%$ 23.318 millions


About Procyon Revenue Growth Rates (PCYN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Procyon Corp (CIK 812306).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-24-032155
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Procyon Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.